Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P181 | DOI: 10.1530/endoabs.56.P181

1Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 2Department of Pituitary and Neuroendocrine Disorders, C. I. Parhon National Institute of Endocrinology, Bucharest, Romania; 3Department of Nephrology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 4Diaverum Nephrology Clinic, Bucharest, Romania.


Background: End stage renal disease is usually associated with high serum parathyroid hormone (PTH) and increased bone turnover. The aim of our study was to correlate serum PTH with serum markers of bone turnover in patients with end stage renal disease (ESRD).

Methods: We measured serum PTH, osteocalcin, procollagen type 1 n-terminal propeptide (P1NP) and beta-crosslaps in 64 (32 men) consecutive pacients, median (25, 75 percentile) age 61 (49.5, 65.5) years, on permanent hemodialysis.

Results: Median (25, 75 percentile) PTH, osteocalcin, P1NP and beta-crosslaps were 246.1 (128, 487.9) pg/mL, 233.9 (96.7, 300) ng/mL, 287.1 (169.9, 810.7) ng/mL and 2.25 (1.63, 3.25) ng/mL, respectively. 90.6%, 96.8% and 93.7% of osteocalcin, P1NP and beta-crosslaps results respectively were higer than the upper limit of normal. We found a positive correlation between serum PTH and bone formation markers osteocalcin (r=0.6136, P<0.001) and P1NP (r=0.6898, P<0.001). There was no correlation between PTH and bone resorbtion marker beta-crosslaps (r=−0.1520, P=0.23).

Conclusion: Bone turnover is increased in end stage renal disease. Beside PTH, osteocalcine and P1NP could also be associated with osteitis fibrosa of ESRD.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.